China Biopharmaceuticals to inject 500 million Cosco ZTE vaccine production capacity or "double"

On December 7, Koxing Holding Biotechnology Co., Ltd. (NasdaqGS:SVA), or "Koxing Holdings"), announced that its subsidiary, Beijing Kexing Zhongwei Biotechnology Co., Ltd. ("Koxing Zhongwei"), had received more than $500 million for the further development, capacity expansion and production of the new coronavirus inactivated vaccine Kellefort™ as well as other development and operation activities of Koxing ZTE.
China Biopharmaceutical Co., Ltd. (01177. HK, referred to as "China Biopharmaceuticals") and its affiliates will receive approximately 15% of the shares of COSCO.
Kelleford, a new crown vaccine developed by Coxing Zhongwei, is one of the five clinical trials currently under way in China, is an inactivated vaccine, has been approved for emergency use in China, and at the same time obtained multi-country vaccine orders.
, which has been working on the vaccine, said it had fully launched production of the new corona inactivated vaccine in August.
addition, the investor is China Biopharmaceutical Co., Ltd. (China Biopharmaceuticals, 001177) and its who whoer-owned subsidiary, Hong Kong Jun-Kong Co., Ltd.
, according to China Biopharmaceuticals' early announcement on December 7, the company and its affiliates entered into an agreement on December 4 for $515 million.
and under the agreement, China Biopharmaceuticals will have a 15.03% interest in the registered capital of Cosco ZTE.
Coxing Zhongwei will be recorded in China Biopharmaceutical's financial statements as an associated company.
believe that through this cooperation, it will further promote the research and development and production capacity of the new crown vaccine of Cosco ZTE.
research and development progress according to the news announced earlier by Koxing, the new crown vaccine I./II. phase clinical study (0,14 procedures) revealed blind, preliminary results show that the vaccine has good safety and immunogenicity.
the new crown inactivated vaccine has also appeared at the China International Trade Fair in Services ( "Service Trade Fair").
mid-October, Zhejiang launched an emergency vaccination of the new crown vaccine, using the vaccine from Koxing.
phase III clinical studies are being conducted in Brazil, Indonesia, Turkey, Chile and other countries.
Production Capacity Coxing Holdings stressed in the official statement that The new crown vaccine production line, which has been completed and put into use, has an annual production capacity of more than 300 million doses and plans to increase the annual production capacity of Klefford to more than 600 million doses when the second production line is completed and put into operation by the end of 2020.
the company may further expand its production capacity in the future, depending on market demand and available funding, with a view to making a greater contribution to the availability and affordability of the new crown vaccine worldwide.
compared with Pfizer's recent announcement that it expects to produce 50m doses of the new crown vaccine this year, compared with the previously announced 100m, due to challenges in the supply chain of raw materials for the new crown vaccine, which means that at Pfizer's current annual production, it will only support 25m people (two per person), which is undoubtedly a cup of water for global demand.
As the author has judged before, how to become the first successful enterprise in the early stages of vaccine research and development is of public concern, and when the real need for vaccination, production and cost will be the difficulties of all vaccine research and development enterprises.
at least annual production may be its biggest competitive advantage, according to the current data released by Koxing, which has received orders for new vaccines from many countries, according to China Biopharmaceuticals.
co-development, mutual benefit and reciprocity on the other hand, the beneficial object of this cooperation can not only be "Koxing Bio", through this investment, to a large extent, also accelerated the pace of China's biopharmaceutical to "whole industry chain" biopharmaceutical enterprises.
At present, China Biopharmaceuticals is China's leading innovative research and development-driven pharmaceutical group, products include a variety of biological drugs and chemicals, in liver disease, tumor, cardiovascular disease, orthopaedics, digestive system, anti-infection and respiratory diseases and other highly promising therapeutic areas in a dominant position.
, Zhengda Tianqing Pharmaceutical Group Co., Ltd. is its core enterprise.
China Biopharmaceuticals said that the combination of vaccines and the Group's existing drugs can improve the Group's product system and broaden the sales pipeline.
a combination of prevention-based vaccines and therapeutic-based pharmaceutical products.
the distribution of vaccines, the Group's business can be extended from the field of disease treatment to the field of disease prevention while driving future business growth.
given the low risk of products in the prevention area being affected by the national drug belt procurement policy, the funding will enhance the Group's overall operational risk resistance.
, entering the field of vaccine research and development and production can also accelerate the Group's transformation and upgrading to "all-industry chain" enterprises.
China Biopharmaceuticals also said the move will speed up the internationalization of the layout, China Biopharmaceuticals will be in overseas markets through the new crown pneumonia vaccine cooperation, commercialization and investment, expand the business network with foreign governments, regulators and business partners, and through the rapid improvement of market position and scale, accelerate and expand the international layout.
Domestic vaccine supply is guaranteed, next year will focus on the world's last, according to Vice Premier Sun Chunlan, State Councilor Wang Yong in the previous research revealed that China currently has 5 technical routes of 14 vaccines into clinical trials, of which 5 vaccines are in accordance with the procedures in accordance with the standards of Phase III.
The production workshops of the five vaccine research and development enterprises of Beijing Science and Technology Co., Ltd., Wuhan Institute of Biology under The National Pharmaceutical Group, Beijing Institute of Biological Research under the National Pharmaceutical Group, Joint Consino Corporation of the Academy of Military Sciences and Anhui Zhifeilong Coma Biopharmaceutical Co., Ltd. have completed construction and have been put into production.
production is expected to total about 1.7 billion to 1.8 billion doses per year.
expected that by the end of this year, China's annual production capacity of the new crown vaccine can reach 610 million doses.
will continue to expand on this basis next year to ensure global supply.
。